HEALTH● LOWAug 14 · Aug 14, 2026, 3:27 PM
Acurx outlines 20-patient PATHFINDER start in Q4 as FDA stays open to a single Phase III ASPIRE for ibezapolstat
Seeking Alpha Tech
Acurx plans to start its 20-patient PATHFINDER trial in Q4, with the FDA remaining open to a single Phase III ASPIRE trial for ibezapolstat. This indicates progress in the development and regulatory pathway for the drug.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH19m agoNigerian newspapers review: [Ebola] FG quarantines high-risk contacts, allays fears of spreadVanguard NigeriaHEALTH51m agoWhat to know about ACA open enrollment this yearCBS NewsHEALTH1h agoBreast cancer in the new era : From early detection to precision oncologytimesofindia.indiatimes.com · IndiaHEALTH1h agoAfrica faces 'complex' Ebola outbreak after spread to Nigeria: WHOFrance 24 [en]